Biocept to Present at Four Virtual Investor Conferences in September

Biocept (Nasdaq: BIOC) has announced that President and CEO Michael Nall will present at four upcoming investor conferences from September 13 to September 30, 2021.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/07/2021 - 08:00 AM EDT

SAN DIEGO--(BUSINESS WIRE)-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:

H.C. Wainwright 23^rd Annual Global Investment Conference being held September 13-15, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m. Pacific time).

Oppenheimer Fall Healthcare Life Sciences & MedTech Conference on Wednesday, September 22, 2021 at 3:45 p.m. Eastern time (12:45 p.m. Pacific time).

Cantor Virtual Healthcare Conference on Wednesday, September 29, 2021 at 4:40 p.m. Eastern time (1:40 p.m. Pacific time).

Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021 at 2:20 p.m. Eastern time (11:20 a.m. Pacific time). The presentation will be available on the Benzinga website here.

Webcasts of the presentations at the Oppenheimer and Cantor conferences will be available on the Events and Presentations page of the Biocept website and will be archived for 90 days.

About Biocept

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.